| 证券代码：301188 | 证券简称：力诺药包 公告编号：2025-048 | | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | 山东力诺医药包装股份有限公司 关于公司控股股东持股比例被动稀释触及 1%整数倍的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益变动主要系山东力诺医药包装股份有限公司（以下简称"公司"） 实施可转换公司债券转股导致公司总股本增加，从而使公司控股股东力诺投资 控股集团有限公司（以下简称"力诺投资"）持有的公司股份比例被动稀释触及 1%整数倍，不涉及持股数量变化、不触及要约收购。 2、本次权益变动不会导致公司控股股东发生变化，不会影响公司的治理 结构和持续经营。 一、本次权益变动的基本情况 根据中国证券监督管理委员会《关于同意山东力诺特种玻璃股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2023]1629 号），公司 向不特定对象发行了 5,000,000 张可转换公司债券，每张面值为人民币 100.00 元，募集资金总额为人民币 500,000, ...

Core Viewpoint - The company announced a temporary suspension of the conversion of its convertible bonds "Lino Convertible Bonds" during the rights distribution period following the approval of the 2024 profit distribution plan at the annual shareholders' meeting on May 15, 2025 [1]. Group 1: Company Announcement - The company will implement the 2024 rights distribution according to relevant regulations [1]. - The suspension of the bond conversion will take place from May 20, 2025, until the equity registration date for the rights distribution [1]. - During the suspension period, the convertible bonds will continue to trade normally [1]. Group 2: Adjustment of Conversion Price - The adjustment of the conversion price for the convertible bonds will occur in the event of stock dividends, capital increases, new share issuances, rights issues, or cash dividends [3]. - Specific formulas for adjusting the conversion price are provided, including adjustments for stock dividends, capital increases, and cash dividends [3]. - The company will announce the adjustment details, including the adjustment date and suspension period, through official channels [4].

| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司 关于实施权益分派期间"力诺转债"暂停转股的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：123221 债券简称：力诺转债 2、转股期限：2024 年 2 月 29 日至 2029 年 8 月 22 日止 3、暂停转股时间：2025 年 5 月 20 日至 2024 年度权益分派股权登记日止 4、恢复转股时间：2024 年度权益分派股权登记日后的第一个交易日 山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过了《关于公司 2024 年度利润分配预案的 议案》，公司将根据相关规定实施 2024 年度权益分派。根据《公司创业板向不 特定对象发行可转换公司债券募集说明书》中"转股价格的调整方式及计算公式" 条款的规定（详见附件）及有关业务办理指南的规 ...

Group 1: Company Performance - In 2024, the company achieved a historical high in revenue of 1.081 billion CNY, representing a year-on-year growth of 14.09% [3] - The net profit attributable to shareholders remained stable at 66.07 million CNY, consistent with the previous year [3] - Total assets reached 2.356 billion CNY, reflecting a year-on-year increase of 9.54% [3] Group 2: Business Strategy and Outlook - The company focuses on the pharmaceutical packaging and heat-resistant glass sectors, aiming to strengthen its position as a market leader [2] - There is an ongoing expansion of production capacity for borosilicate products, with expectations for continued growth in the future [3] - The company plans to enhance its market share in the pharmaceutical packaging sector by leveraging its technical reserves and customer resources [3] Group 3: Share Buyback and Financial Management - As of May 13, the company has repurchased 2,325,800 shares, accounting for 1.00% of the total share capital [4] - The buyback plan will continue based on market conditions [4] Group 4: International Expansion - The company has prioritized global development, with significant progress in Latin America and the Middle East [5] - In January 2024, the company signed an investment framework agreement to acquire 51% of The European Ampoules Company in Egypt [5] - A cooperation investment agreement was signed with SANTISA ABORATORIO FARMACEUTICO S/A in March 2025 to further expand market reach [6]

Group 1: Financial Performance - The company's revenue for 2024 is projected to grow by 14.09% compared to 2023, driven by strong market demand and strategic focus on pharmaceutical packaging [2] - Research and development (R&D) investment for 2024 is set at 33.79 million RMB, reflecting a 12.16% increase from 2023 [3] Group 2: Business Strategy - The company aims to expand its production capacity and enhance market development efforts, particularly in pharmaceutical packaging [2][7] - Plans to accelerate the transformation of high borosilicate glass business and focus on new product development and channel expansion [4][7] Group 3: International Expansion - The company is prioritizing global development, with a focus on Latin America and the Middle East, having signed investment agreements in Egypt and Brazil [5][6] Group 4: Internal Management and Risk Mitigation - Continuous improvement in internal management is a key focus, including the introduction of high-level talent and enhancement of digital and automated processes to reduce production costs [8] - The company plans to establish independent subsidiaries for brand promotion and sales, enhancing its market presence [4][8] Group 5: Share Buyback Plan - The company has approved a share buyback plan, intending to repurchase between 50 million and 100 million RMB worth of its A-shares [9][10]

特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过决议的情形。 | 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 （一）会议召开情况 1、股东大会届次：2024 年年度股东大会 2、会议召开的时间： （1）会议召开时间：2025 年 5 月 15 日（星期四）14:40 （2）网络投票时间：通过深圳证券交易所（"深交所"）交易系统进行网 络投票的具体时间为：2025 年 5 月 15 日 9:15-9:25、9:30—11:30，13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 15 日 9:15-15:00。 3、会议的召开方式：本次股东大会采用现场投票与网络投票相结合的方式 4、会议召开地点：山 ...

北京市中伦律师事务所 关于山东力诺医药包装股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年五月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关于山东力诺医药包装股份有限公司 2024 年年度股东大会的 法律意见书 致：山东力诺医药包装股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为山东力诺医药包装股份有 限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司 2024 年年度股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民 ...

Group 1: Company Overview - The company is Shandong Linuo Medical Packaging Co., Ltd., with stock code 301188 and bond code 123221 [1]. Group 2: Investor Relations Activity - An investor relations activity was held on May 15, 2025, from 15:00 to 16:30 via an online platform [2]. - The meeting included a Q&A session where investors posed questions to the company representatives [2]. Group 3: Product Development and Branding - The company is establishing a high-end heat-resistant kitchen glass e-commerce brand in China, with a dedicated product design center and brand promotion center [2]. - A subsidiary has been set up in Hangzhou for promoting its own brands, including domestic brand "Lebole" and international brand "borohouse," which have been successfully registered and are being sold through domestic and international e-commerce channels [2]. Group 4: Growth Opportunities - The pharmaceutical packaging sector is experiencing significant growth opportunities, with strong market demand [3]. - The company plans to focus on expanding production capacity and enhancing market development efforts, particularly in high borosilicate heat-resistant glass products [3]. - Continuous development of new products and channels is emphasized to improve operational performance [3].

证券代码：301188 证券简称：力诺药包 公告编号：2025-045 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 山东力诺医药包装股份有限公司（以下简称"公司"）于2025年2月7日召开 第四届董事会第八次会议和第四届监事会第七次会议，审议通过了《关于回购公 司股份方案的议案》，拟使用公司自有资金及股票回购专项贷款资金不低于人民 币5,000万元（含），不超过人民币10,000万元通过深圳证券交易所交易系统以 集中竞价交易的方式回购公司发行的人民币普通股（A股）股票，回购价格不超 过22.00元/股（含本数），回购股份用于实施股权激励计划或者员工持股计划， 回购期限自董事会审议通过回购股份方案之日起12个月内。公司已在中国证券登 记结算有限责任公司深圳分公司开立了回购股份专用证券账户。具体内容详见公 司于2025年2月7日在巨潮资讯网披露的《关于回购公司股份方案暨取得金融机构 股票回购专项贷款承诺函的公告》（公告编号：2025-008）及公司于2025年2月 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 应当在事实发生之日起三个交易日内予以披露，现将公司回 ...

Group 1 - The company, Lino Pharmaceutical (301188), has repurchased a total of 2.3258 million shares, which accounts for 1.00% of its total share capital [1] - The highest transaction price for the repurchased shares was 17.97 yuan per share, while the lowest was 15.66 yuan per share [1] - The total amount spent on the share repurchase was 39.2522 million yuan, excluding transaction fees [1] Group 2 - The share repurchase complies with relevant laws and regulations as well as the company's repurchase plan [1]